Webb A R
UCL Hospitals, London, UK.
Crit Care. 2000;4 Suppl 2(Suppl 2):S26-32. doi: 10.1186/cc967. Epub 2000 Oct 13.
Three meta-analyses have recently been reported on the relationship between choice of resuscitation fluid and risk of mortality in critically ill patients. The relative risk of death (1.16-1.19) in two of the meta-analyses was slightly higher in colloid than crystalloid recipients; however, this observation was not statistically significant. In the third meta-analysis, 6% (95% confidence interval [CI], 3-9%) pooled excess mortality was documented in patients receiving albumin for hypovolaemia, burns or hypoalbuminaemia. The mortality difference in hypovolaemia patients (4%; 95% CI, 0-8%) was not statistically significant. A variety of serious limitations apply to the three meta-analyses, suggesting that their findings be interpreted cautiously. More than one-half of the randomized controlled trials (RCTs) included in the meta-analyses were reported prior to 1990 and hence do not reflect current practice. Each meta-analysis included only a subset of relevant RCTs, and therefore the scope of inferences to be drawn from the meta-analytic results is limited. The meta-analyses combined RCTs that were notably heterogeneous with respect to patient characteristics, type of illness, administered fluids and physiologic endpoints. Differences in illness severity, concomitant therapies and fluid management approaches were not taken into account. Very few of the RCTs were blinded. The meta-analyses do not support the conclusion that choice of resuscitation fluid is a major determinant of mortality in critically ill patients, nor do they support changes to current fluid management practice. Changes such as exclusive reliance on crystalloids would necessitate a reassessment of the goals and methods of fluid therapy. Since the effect on mortality may be minimal or non-existent, choice of resuscitation fluid should rest on whether the particular fluid permits the intensive care unit to provide better patient care.
最近有三项关于危重症患者复苏液体选择与死亡风险之间关系的荟萃分析报告。其中两项荟萃分析显示,接受胶体液的患者死亡相对风险(1.16 - 1.19)略高于接受晶体液的患者;然而,这一观察结果无统计学意义。在第三项荟萃分析中,接受白蛋白治疗低血容量、烧伤或低白蛋白血症的患者记录到6%(95%置信区间[CI],3 - 9%)的合并额外死亡率。低血容量患者的死亡率差异(4%;95% CI,0 - 8%)无统计学意义。这三项荟萃分析存在多种严重局限性,表明其结果应谨慎解读。荟萃分析纳入的随机对照试验(RCT)中,超过一半是1990年之前报告的,因此不能反映当前的实践情况。每项荟萃分析仅纳入了相关RCT的一个子集,因此从荟萃分析结果得出的推论范围有限。这些荟萃分析合并了在患者特征、疾病类型、给予的液体和生理终点方面显著异质的RCT。未考虑疾病严重程度、伴随治疗和液体管理方法的差异。RCT中很少有采用盲法的。这些荟萃分析既不支持复苏液体选择是危重症患者死亡率的主要决定因素这一结论,也不支持改变当前的液体管理实践。诸如完全依赖晶体液等改变将需要重新评估液体治疗的目标和方法。由于对死亡率的影响可能很小或不存在,复苏液体的选择应取决于特定液体是否能使重症监护病房提供更好的患者护理。